论文部分内容阅读
目的了解在对溴隐亭耐药和有效的泌乳素腺瘤患者间,早期血清PRL水平是否存在差异。方法收集了105例垂体泌乳素腺瘤患者的临床资料,根据溴隐亭疗效分为有效组和耐药组,其中有效组86例,耐药组19例。对两组患者药物治疗前血清PRL水平进行比较。结果有效组中患者早期血清PRL水平为(689.4±136.9)μg/L高于耐药组的(410.9±121.9)μg/L,差异有统计学意义(P<0.05)。结论血清PRL水平高的患者可能对药物有敏感性倾向,但要准确预测耐药现象,还应当结合分子生物学相关指标。多巴胺D2受体及其两种亚型D2 s(short)和D2 l(long)在肿瘤组织中的表达水平与耐药现象的相关性,值得进一步研究。
Objective To understand whether early serum PRL levels differ between bromocriptine-resistant and effective prolactin adenoma patients. Methods The clinical data of 105 patients with pituitary prolactinoma were collected. According to the efficacy of bromocriptine, the efficacy was divided into effective group and drug resistance group, 86 cases in effective group and 19 cases in drug resistance group. The serum PRL levels before drug treatment were compared between the two groups of patients. Results The serum level of PRL in the effective group was (689.4±136.9)μg/L, which was higher than that in the resistant group (410.9±121.9)μg/L. The difference was statistically significant (P<0.05). Conclusions Patients with high serum PRL levels may have a tendency to be sensitive to drugs, but to accurately predict resistance, they should also incorporate molecular biology-related indicators. The correlation between the expression of dopamine D2 receptor and its two subtypes, D2 s (short) and D2 l (long), in tumor tissues and drug resistance is worth further study.